Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Glucantime injection: benefit versus toxicity].

A Masmoudi1, N Maalej, M Mseddi

  • 1Service de dermatologie, EPS, CHU Hédi-Chaker, 3029 Sfax, Tunisie. masmoudiabd@yahoo.fr

Medecine Et Maladies Infectieuses
|February 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STSM 2025 & 2nd African Medical Writing Congress.

La Tunisie medicale·2026
Same author

Predictive factors for non-response to intravitreal bevacizumab in diabetic macular edema.

Journal francais d'ophtalmologie·2026
Same author

Enriching African genome representation through the AGenDA project.

Nature·2026
Same author

Photic maculopathy: OCT-angiography features of eight eyes.

Archivos de la Sociedad Espanola de Oftalmologia·2025
Same author

Very short-term efficacy of selective laser trabeculoplasty in primary open-angle glaucoma.

Journal francais d'ophtalmologie·2025
Same author

Assessment of optic nerve head microvascular changes with OCT angiography in diabetic patients without diabetic retinopathy.

Journal francais d'ophtalmologie·2025

Adverse effects from Glucantime injections for cutaneous leishmaniasis (CL) are common in Tunisia. While most reactions like rash and joint pain are mild, serious issues such as acute renal failure can occur.

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Glucantime (meglumine antimoniate) is a primary treatment for cutaneous leishmaniasis (CL) in Tunisia.
  • Reported adverse effects necessitate further investigation into its safety profile.

Purpose of the Study:

  • To retrospectively analyze the adverse effects of intramuscular Glucantime in patients with CL.
  • To identify the types and severity of adverse events associated with Glucantime treatment.

Main Methods:

  • Retrospective study design.
  • Analysis of patient data receiving intramuscular Glucantime for CL.
  • Documentation and categorization of reported adverse effects.

Main Results:

Related Experiment Videos

  • Nineteen patients (21%) experienced adverse effects.
  • Common side effects included skin rash (4), arthralgia/myalgia (4), and fever (3).
  • Serious adverse events, including acute renal failure (3 cases, 1 fatal) and hepatic cytolysis (1 case), were observed.

    • Conclusions:

    • Adverse effects of intramuscular Glucantime are frequent in CL patients.
    • Mild effects like arthralgia, myalgia, and skin rash resolved upon treatment cessation.
    • Severe stibiointoxication, particularly acute renal failure, poses a significant risk.